HUMACYTE INC

NASDAQ: HUMA (Humacyte, Inc.)

Kemas kini terakhir: 2 hari lalu, 9:25PM

5.10

-0.08 (-1.54%)

Penutupan Terdahulu 5.18
Buka 5.13
Jumlah Dagangan 3,189,547
Purata Dagangan (3B) 4,740,867
Modal Pasaran 656,206,784
Harga / Buku (P/B) 30.28
Julat 52 Minggu
2.48 (-51%) — 9.97 (95%)
Tarikh Pendapatan 20 Mar 2025 - 24 Mar 2025
EPS Cair (TTM) -1.34
Jumlah Hutang/Ekuiti (D/E MRQ) 71.00%
Nisbah Semasa (MRQ) 1.10
Aliran Tunai Operasi (OCF TTM) -90.60 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -58.33 M
Pulangan Atas Aset (ROA TTM) -53.23%
Pulangan Atas Ekuiti (ROE TTM) -850.81%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Humacyte, Inc. Menaik Menaik

AISkor Stockmoo

1.5
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 1.0
Osilator Teknikal 2.0
Purata 1.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
HUMA 656 M - - 30.28
CYTK 6 B - - 60.31
ARWR 2 B - - 13.19
FTRE 2 B - - 1.14
REPL 971 M - - 2.24
ABUS 648 M - - 5.83

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 26.87%
% Dimiliki oleh Institusi 30.02%

Pemilikan

Nama Tarikh Syer Dipegang
Monashee Investment Management Llc 30 Sep 2024 535,000
Julat 52 Minggu
2.48 (-51%) — 9.97 (95%)
Julat Harga Sasaran
10.00 (96%) — 25.00 (390%)
Tinggi 25.00 (D. Boral Capital, 390.20%) Beli
25.00 (EF Hutton, 390.20%) Beli
Median 16.00 (213.73%)
Rendah 10.00 (TD Cowen, 96.08%) Beli
10.00 (BTIG, 96.08%) Beli
Purata 17.00 (233.33%)
Jumlah 6 Beli
Harga Purata @ Panggilan 4.90
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Benchmark 23 Dec 2024 17.00 (233.33%) Beli 4.65
10 Oct 2024 15.00 (194.12%) Beli 5.55
D. Boral Capital 20 Dec 2024 25.00 (390.20%) Beli 4.64
21 Nov 2024 25.00 (390.20%) Beli 4.38
HC Wainwright & Co. 20 Dec 2024 15.00 (194.12%) Beli 4.64
18 Nov 2024 12.00 (135.29%) Beli 4.45
EF Hutton 28 Oct 2024 25.00 (390.20%) Beli 5.42
BTIG 18 Oct 2024 10.00 (96.08%) Beli 5.03
TD Cowen 18 Oct 2024 10.00 (96.08%) Beli 5.03

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
19 Dec 2024 Pengumuman Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
02 Dec 2024 Pengumuman Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
23 Nov 2024 Pengumuman HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025
22 Nov 2024 Pengumuman Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
22 Nov 2024 Pengumuman HUMACYTE DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on January 17, 2025
21 Nov 2024 Pengumuman Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
21 Nov 2024 Pengumuman Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
21 Nov 2024 Pengumuman HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
20 Nov 2024 Pengumuman Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
19 Nov 2024 Pengumuman Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
18 Nov 2024 Pengumuman Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
14 Nov 2024 Pengumuman Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
08 Nov 2024 Pengumuman Humacyte Third Quarter 2024 Financial Results and Business Update
06 Nov 2024 Pengumuman Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
28 Oct 2024 Pengumuman Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
23 Oct 2024 Pengumuman Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
22 Oct 2024 Pengumuman Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
21 Oct 2024 Pengumuman Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
19 Oct 2024 Pengumuman Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
08 Oct 2024 Pengumuman Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda